Frontotemporal Dementia - Epidemiology Forecast - 2036

Frontotemporal Dementia (FTD) Insights and Trends

• According to DelveInsight's analysis, the total diagnosed prevalent cases of FTD were ~130,300 in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• FTD is a neurocognitive condition causing progressive dysfunction in executive functioning, behavior, and language.
• FTD, sometimes called frontotemporal disorders, is rare and tends to occur at a younger age than other dementias. About 60% of people with frontotemporal dementia are 45-64 years old.
• Symptoms can differ significantly, ranging from behavioral and emotional disturbances to difficulties with communication and motor function. Risk is higher in individuals with a family history of FTD, with approximately 15-40% of cases associated with genetic mutations. However, in most cases, the underlying cause remains unknown.
• Behavioral variant Frontotemporal Dementia (bvFTD) causes early personality and behavioral changes, while Primary Progressive Aphasia (PPA) primarily impairs language abilities, both typically presenting in midlife.
• The diagnosed prevalence of FTD shows a higher proportion of non-mutated cases (60%) compared to mutation-associated cases (40%), indicating that most FTD cases are sporadic, though a substantial genetic component remains significant.
• Diagnosing FTD presents challenges due to its varied symptoms that overlap with other conditions, lack of specific biomarkers, and the need for comprehensive clinical assessments. Misdiagnosis is common, as FTD symptoms can mimic psychiatric disorders or other dementias, complicating accurate and timely identification.

DelveInsight's 'Frontotemporal Dementia (FTD) - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the FTD, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Frontotemporal Dementia (FTD) Understanding and Diagnosis Algorithm

Frontotemporal Dementia (FTD) Overview and Diagnosis

FTD is a neurodegenerative disorder characterized by loss of intellectual functions, such as memory problems, impaired abstract thinking, reasoning, and executive function that are severe enough to hamper activities of daily living. The clinical manifestations include behaviour changes, dietary changes, loss of empathy, apathy, and executive function. It is the second most common form of dementia in individuals under 65 years of age.

There are a number of different diseases that cause frontotemporal degeneration. The two most prominent are a group of brain disorders involving the protein tau and a group of brain disorders involving the protein called TDP43.

Frontotemporal Dementia (FTD) Diagnosis

FTD is a complex process due to its symptom overlap with other neurological conditions. Since there is no single definitive test for FTD, healthcare professionals rely on multiple diagnostic approaches. Clinical evaluation plays a crucial role in assessing behavioural and cognitive symptoms, helping to differentiate FTD from other forms of dementia. Blood tests are often conducted to rule out other medical conditions such as liver or kidney disease that might cause similar symptoms. Neuropsychological testing further aids in evaluating reasoning and memory skills, offering additional insight into cognitive impairments specific to FTD. Brain imaging techniques are also fundamental in diagnosis; magnetic resonance imaging (MRI) helps detect structural changes in the frontal and temporal lobes, while fluorodeoxyglucose positron emission tomography (FDG-PET) scans identify areas of decreased metabolism, which can indicate neurodegeneration.

Frontotemporal Dementia (FTD) Epidemiology

Key Findings from Frontotemporal Dementia (FTD) Epidemiological Analysis and Forecast

• According to DelveInsight's analysis, the total diagnosed prevalent cases of FTD in 7MM were found to be ~130,300 in 2025 and are estimated to rise with a significant CAGR throughout the forecast period (2026-2036).
• FTD represents an estimated 10-20% of all dementia cases.
• The highest proportion of FTD cases were observed in the bvFTD in the 7MM, while the least cases were found in language variant FTD (primary progressive aphasia).
• In EU4 and the UK, a decreasing trend in observed for Germany and Italy, where the diagnosed prevalent cases of FTD are expected to decrease throughout the forecast period (2026-2036).
• In 2025, the US recorded the highest number of diagnosed prevalent cases of C9orf72 (~40%) gene-specific FTD, followed by cases associated with the GRN (Progranulin) gene-specific mutation.

Scope of the Report:

• The report covers a segment of an executive summary, a descriptive overview of FTD, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Frontotemporal Dementia (FTD) Patient Population Forecast

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of FTD? What will be the growth opportunities across the 7MM concerning the patient population with FTD?
• What is the historical and forecasted FTD patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.